A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
about
Novel drugs that target the metabolic reprogramming in renal cell cancerJudicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and PerspectivesTargeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma.Inhibiting 4EBP1 in glioblastoma.New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.Recent advances in targeting mTOR signaling pathway using small molecule inhibitors.mTORC1 and mTORC2 in cancer and the tumor microenvironment.Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.Uncoupling TORC2 from AGC kinases inhibits tumour growth.Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients.Clinical development of mTor inhibitors for renal cancer.Influence of the Novel ATP-Competitive Dual mTORC1/2 Inhibitor AZD2014 on Immune Cell Populations and Heart Allograft Rejection.Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials.RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.Synergy of WEE1 and mTOR Inhibition in Mutant KRAS-Driven Lung Cancers.
P2860
Q26740187-09ED5635-D796-41B5-8A28-A118195640F2Q28071388-B4E34DB5-2AEB-4FD2-A05A-5FFBD89D0002Q33798463-8BE69ACB-D40F-402F-B9E4-EAF56BBEBEC7Q37091157-75E37FEC-69B8-4DD7-8F6F-5DD06B8DB743Q38659417-2A175F62-D033-4E01-BA95-ECDED08B77D1Q38711763-72D35273-B723-4EB6-BEA6-1536A8CED8D6Q38914374-9F54514D-663B-49BC-94CB-DB3D6F1C2761Q38955246-918C9CA0-C4D1-4553-A3D1-71BC5394682EQ38982579-A063D2C3-F82F-4040-A0C3-2924C7822ECDQ39008859-277B3D52-BA05-4FA1-A6E5-DEA6529FEABCQ41491779-5CF6BE50-B852-4F87-A173-23683E2F32E8Q46156033-FC0E19D0-1AA4-406A-A71D-191181E55939Q47320024-A2AAA3DE-0AA2-4B63-AAF8-A19199B4CE40Q47737687-621DF821-76DE-4B59-9687-066DA7F83D2CQ47835201-904C8915-4D90-4462-A01E-4EE1BB05C66DQ48097821-E3BE14BF-2CBB-4A3F-BDF7-F091F820762AQ48123819-5306CC65-E87C-4BBE-A2DB-B27CA96A1B8FQ48689511-FC3E1CA3-CEF1-449C-BE65-202BB0083682
P2860
A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A Randomised Phase 2 Study of ...... tatic Clear Cell Renal Cancer.
@en
A Randomised Phase 2 Study of ...... tatic Clear Cell Renal Cancer.
@en-gb
type
label
A Randomised Phase 2 Study of ...... tatic Clear Cell Renal Cancer.
@en
A Randomised Phase 2 Study of ...... tatic Clear Cell Renal Cancer.
@en-gb
prefLabel
A Randomised Phase 2 Study of ...... tatic Clear Cell Renal Cancer.
@en
A Randomised Phase 2 Study of ...... tatic Clear Cell Renal Cancer.
@en-gb
P2093
P50
P1433
P1476
A Randomised Phase 2 Study of ...... static Clear Cell Renal Cancer
@en
P2093
Akhila Wimalasingham
Andrew Stockdale
Angus Robinson
Ekaterini Boleti
Imtiaz Ahmed
Shah-Jalal Sarker
Thomas Geldart
Thomas Powles
Wendy Burke
P304
P356
10.1016/J.EURURO.2015.08.035
P407
P577
2015-09-11T00:00:00Z